Alvotech SA (NASDAQ:ALVO), a biotechnology company focused on biosimilar medicines, reported its fourth quarter and full-year 2025 financial results. The figures reveal a company delivering strong top-line growth but facing a significant bottom-line miss against analyst expectations, a dynamic that appears to be weighing on investor sentiment in after-hours trading.
Earnings and Revenue Versus Estimates
The core financial metrics for Q4 2025 presented a mixed picture. The company's revenue performance exceeded Wall Street's forecasts, while its earnings per share fell notably short.
- Revenue: Alvotech reported Q4 revenues of $168.9 million. This surpassed the analyst consensus estimate of $163.1 million, representing a beat of approximately 3.5%.
- Earnings Per Share (EPS): The company reported a non-GAAP EPS loss of $0.37 for the quarter. This was a substantial miss compared to the estimated loss of $0.0459, indicating much higher operational costs or other adjustments than analysts had modeled.
For the full year 2025, the company reported total revenues of $593 million, a 21% increase year-over-year, and an adjusted EBITDA of $137 million, up 27%.
Market Reaction and Price Action
The market's immediate reaction to the earnings release was negative. Following the announcement, Alvotech's stock was down approximately 2.6% in after-market trading. This decline suggests investors are focusing more on the significant EPS miss and the associated costs than on the revenue beat. The stock's performance over recent weeks has been volatile, with a slight gain over the past week but declines over the past two weeks and month, indicating pre-earnings uncertainty.
Management's Outlook Versus Analyst Projections
A key component of the earnings release was management's reaffirmed financial outlook for the full year 2026. The company anticipates total revenues in the range of $650 to $700 million and adjusted EBITDA between $180 and $220 million.
This company-provided guidance stands in stark contrast to current analyst estimates, which are significantly higher. Wall Street analysts, on average, are forecasting sales of approximately $811.6 million for FY 2026. Alvotech's revenue guidance, even at the high end of its range, is roughly 14% below this consensus. The company explicitly noted that the lower end of its range assumes no new U.S. product launches in 2026, pointing to regulatory timelines as a key variable and potential headwind.
Key Operational Highlights from the Report
Beyond the financials, the press release outlined several important operational milestones achieved in 2025:
- Product Approvals and Pipeline: The company gained regulatory approvals in Europe for AVT05 (a Simponi® biosimilar) and AVT03 (a Prolia®/Xgeva® biosimilar). A marketing application for AVT23 (referencing Xolair®) was accepted for review by the European Medicines Agency (EMA).
- U.S. Market: The company's second biosimilar in the U.S., Selarsdi™ (a Stelara® biosimilar), was launched by partner Teva.
- Strategic Moves: Alvotech expanded its capabilities through the acquisitions of Xbrane’s R&D organization in Sweden and the Ivers-Lee Group in Switzerland. It also broadened its investor base with a listing on Nasdaq Stockholm.
- Leadership and Regulatory Path Forward: A significant leadership transition was confirmed, with Lisa Graver appointed as the new Chief Executive Officer. Regarding a persistent challenge, the company stated it has addressed observations from a prior FDA inspection of its Reykjavik facility and expects to resubmit the affected applications in the second quarter of 2026, targeting U.S. approvals by late 2026.
Conclusion
Alvotech's latest earnings report underscores its continued commercial execution and pipeline progress, particularly in ex-U.S. markets, as evidenced by its revenue growth. However, the substantial earnings miss and a 2026 revenue guidance range that sits well below current analyst expectations have introduced caution. The market's negative after-hours reaction reflects concerns over profitability and the timeline for resolving U.S. regulatory hurdles, which are critical for unlocking the next phase of growth. Investors will likely focus on the company's progress toward its FDA resubmission goal and subsequent launch timelines in the coming quarters.
For more detailed historical earnings data and future analyst projections and estimates, you can review the information available here: ALVO Earnings and ALVO Analyst Forecasts.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.